Actinic Keratosis Treatment Market Research Report - Forecast till 2030

Actinic Keratosis Treatment Market: Information By Type (Medications and Procedures), By End User (Hospitals & Oncology Centers, Dermatology Clinics and Ambulatory Surgical Center) - Forecast till 2030

ID: MRFR/Pharma/1746-CR | July 2019 | Region: Global | 95 Pages         

Actinic Keratosis Treatment Market Speak to Analyst Request a Free Sample

Actinic Keratosis Treatment Market

Actinic Keratosis Treatment Market Is Projected To Reach $3,548 million, Enlisting a CAGR Of 6.2% By 2030.

By Type Medications Procedures
By End-User Hospitals & Oncology Centers Dermatology Clinics Ambulatory Surgical Center
By Medication fluorouracil cream imiquimod cream Ingenol mebutate gel diclofenac gel
By Based on Procedure crytherapy photodynamic therapy laser chemical peel others
Key Players
Companies Profiled   Stanford Chemicals (US)   Alma Lasers (Israel)   3M (US)   Sun Pharmaceutical Industries Ltd. (India)   Galderma S.A (Switzerland)   Leo Pharma (Denmark)   Valeant Pharmaceuticals (US)   BioLineRx (Israel)
Market Driving Forces   Growing Geriatric Population   Increasing Prevalence Of Actinic Keratosis
Request a Free Sample

Actinic Keratosis Market Overview

The Actinic Keratosis Treatment Market is anticipated to reach USD 3,548 Million by 2030 at 6.2% CAGR during the forecast period 2022-2030.

COVID-19 Analysis of Actinic Keratosis Market 

The global pandemic has disrupted multiple businesses and countries since the spread of the COVID-19 virus in December 2019. It has also been declared a global health emergency by the World Health Organisation. The global impact of coronavirus disease 2019 (COVID-19) is now beginning to be felt and will have a major impact on the actinic keratosis market in 2020. The epidemic of COVID-19 has had an effect on many aspects, such as flight cancellations; travel bans and quarantines; restaurants closed; all indoor/outdoor activities restricted; more than 40 countries declared a state of emergency; massive supply chain slowdown; stock market volatility; deteriorating corporate morale, increasing public fear and confusion about the future.

Actinic Keratosis Market Dynamics


Adoption of minimally-invasive clinical treatments drives market growth

MRFR projects that the rising incidence of actinic keratosis market, the increasing adoption of minimally invasive clinical treatments, the presence of adequate medical coverage and the growing geriatric population are the drivers of demand development. In the meantime, the improved medical reimbursement environment has given rise to a stronger reaction from the patient. A variety of healthcare providers have begun to offer prescription coverage for selected procedures for actinic keratosis. Such policies have augured well for healthcare providers and patients alike.. 


Growing Government Initiatives to Create Growth Avenues for the Key Players

Government programmes to make healthcare facilities more affordable and available have also affected the number of patients participating in actinic keratosis therapy. The presence of attractive rebate programmes is projected to fuel demand growth during the forecast period.


High Cost of Treatment Impedes Market Growth

However, the high cost of treatments and complications involved with the care modules currently available are some of the bottlenecks that have yet to be tackled. The clinical cost of procedures such as laser skin surfaces is high. Factors as such have a negative effect on the overall growth of the sector.

Actinic Keratosis Market Segmental Analysis

Global Actinic Keratosis Treatment Market has been segmented into Type, Medication, Procedure, and End User. 

Based on the procedure, the actinic keratosis market is divided into cryotherapy, photodynamic therapy, laser, chemical peel, and others. Among these, the cryosurgery segment had the largest market share in 2017 and is expected to have a high CAGR during the forecast period. Cryotherapy is a widely used medication for actinic keratosis, although creating successful photodynamic therapy is expected to remain a primary focus for major players in the market for actinic keratosis in the coming years..

By medication, the actinic keratosis market is segmented into imiquimod cream, fluorouracil cream, Ingenol mebutate gel, and diclofenac gel. The diclofenac gel segment is expected to have risen comparatively faster than in 2024.

The actinic keratosis market is segmented into drugs and procedures on the basis of the type. In 2017, the procedural division held the largest market share and is likely to outperform the former over the evaluation period. This is partly due to the performance, quick outcomes and ease of use of procedures.

On the basis of end-users, the industry is segmented into hospitals & oncology centres, dermatology clinics, outpatient surgery centres, and others. The hospital and oncology centre market is projected to remain extremely lucrative in 2018 and beyond, as hospitals and oncology centres have a high incidence of patients. Hospitals and oncology centres are expected to hold a commanding actinic keratosis market share in the global market for actinic keratosis over the projected period, with dermatology diagnostic clinics emerging as another leading segment of the actinic keratosis market.

Actinic Keratosis Market Regional Analysis

The geographical overview of the global actinic keratosis market has been conducted in four major regions, including the Asia Pacific, North America, Europe, and the Middle East and Africa.

North America leads the Americas with established end-use Sectors

The Americas is dominated by North America and is likely to be the major regional segment of the global actinic keratosis market over the forecast period. The simple availability in North America of advanced therapeutic treatments, including both combination therapy and monotherapy, is expected to be the key driver of the actinic keratosis market over the forecast period. More than 40 percent market share was jointly accounted for by North America and South America in 2017. In specific, North America provides major prospects for players in the industry. The growth of the industry in North America is influenced by factors such as the involvement of major suppliers, the growing prevalence of actinic keratosis, and increased demand for minimally invasive procedures. Growing efforts in cancer research in North America are also expected to fuel the demand for actinic keratosis over the projected period, as therapies for actinic keratosis play a critical role in stopping cancer tumours from developing and thereby helping to reduce the pressure on the healthcare system caused by the increasing incidence of cancer.

Germany to Lead Europe Market

Europe currently holds the second positing in the global actinic keratosis market. The demand in the area is projected to grow exponentially by the end of 2030. It is anticipated that the growing number of recorded cases of actinic keratosis and increasing medical tourism will fuel business growth in this area.

APAC to account as Fastest Growing Region

Due to the emerging geriatric population, Asia-Pacific is expected to be the fastest-growing market and the high prevalence of the disease in southern areas, such as Australia and New Zealand, is likely to create strong opportunities for actinic keratosis market players in this field. Medical tourism has emerged as a highly lucrative avenue for Asia Pacific players in the medical industry and is expected to expand steadily in the coming years, offering steady support for the region's rise in the demand for actinic keratosis.

The Middle East & Africa accounted for the least actinic keratosis market share in 2017, with the presence of low-income countries and strict government regulations.

Actinic Keratosis Market- Competitive Landscape

In the global market for actinic keratosis therapy, the leading players are

  • Stanford Chemicals (US)

  • Alma Lasers (Israel), 

  • 3M (US),

  • Sun Pharmaceutical Industries Ltd. (India),

  • Galderma S.A (Switzerland),

  • Leo Pharma (Denmark),

  • Valeant Pharmaceuticals (US),

  • BioLineRx (Israel),

  • Cipher Pharmaceuticals Inc (Canada),

  • Biofrontera AG (Germany)

Recent Development

December 2020: Athenex, Inc., a multinational biopharmaceutical corporation devoted to the research, production and promotion of innovative cancer treatment treatments and associated disorders, reported that Klisyri (tirbanibulin) has been authorised by the FDA for topical treatment of actinic keratosis (AK) in the face or scalp. Klisyri was the first branded patented medication approved by the FDA for Athenex to be introduced in the United States in 2021 in collaboration with Almirall. Athenex will deliver Klisyri, demonstrating the vertically integrated capabilities of the company, spanning from a preclinical lead to a mature product for commercial launch.

November 2020: Jupiter Wellness, Inc. announced its plan to lauch a clinical trial of its CaniSun sunscreen lotion for the treatment of actinic keratosis (AK), the most prevalent precancer caused by exposure to ultraviolet (UV) rays on the skin.

Report Overview

By Type

  • Medications

  • Procedures

By End-User

  • Hospitals & Oncology Centers

  • Dermatology Clinics

  • Ambulatory Surgical Center

By Medication

  • fluorouracil cream

  • imiquimod cream

  • Ingenol mebutate gel

  • diclofenac gel

By Based on Procedure

  • crytherapy

  • photodynamic therapy

  • laser

  • chemical peel

  • others

Report Scope:

Report Attribute/Metric Details
  Market Size   USD 3,548 Million
  CAGR   6.2%
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Billion)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Medication, Procedure, and End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Stanford Chemicals (US), Alma Lasers (Israel), 3M (US), Sun Pharmaceutical Industries Ltd. (India), Galderma S.A (Switzerland), Leo Pharma (Denmark), Valeant Pharmaceuticals (US), BioLineRx (Israel), Cipher Pharmaceuticals Inc (Canada), Biofrontera AG (Germany
  Key Market Opportunities   Growing Markets Of Asia-Pacific
  Key Market Drivers

  • Increasing Prevalence Of Actinic Keratosis
  • Rising Demand And Acceptance Of Minimally Invasive Therapeutic Procedures
  • Suitable Medical Coverage For A Variety Of Treatment Options Available In The Market
  • Growing Geriatric Population
  • Drivers Impact Analysis

  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    The actinic keratosis treatment market CAGR would be 6.2% during the forecast period.

    The restraining factors of the market are high cost and various associated risks.

    The Americas would dominate the Actinic Keratosis Treatment Market.